Although Tezepermab, a biologic that targets TSLP for treatment, was reported to reduce the frequency of asthma exacerbations [108], the role of ILCS2, including IL25 and IL-33, is not fully understood, and we need to elucidate the full mechanism of its production and develop new treatment options. This evidence concerns the gene IL33 and asthma.